Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor
Z Kaymakcalan, P Sakorafas, S Bose, S Scesney… - Clinical …, 2009 - Elsevier
The TNF antagonists adalimumab, infliximab, and etanercept are effective treatments for
rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and psoriasis, but only
adalimumab and infliximab have been found to be efficacious in Crohn's disease. The
present studies evaluated the TNF-binding and complement-activating properties of
adalimumab, infliximab, and etanercept to determine whether these properties may explain
differences in their clinical efficacy profiles. Association and dissociation rates of binding to …
rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and psoriasis, but only
adalimumab and infliximab have been found to be efficacious in Crohn's disease. The
present studies evaluated the TNF-binding and complement-activating properties of
adalimumab, infliximab, and etanercept to determine whether these properties may explain
differences in their clinical efficacy profiles. Association and dissociation rates of binding to …